Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline

• Published in: Journal of clinical oncology Vol. 38; no. 23; pp. 2677 - 2694
• Main Authors: Shah, Manish A, Kennedy, Erin B, Catenacci, Daniel V, Deighton, Dana C, Goodman, Karyn A, Malhotra, Narinder K, Willett, Christopher, Stiles, Brendon, Sharma, Prateek, Tang, Laura, Wijnhoven, Bas P L, Hofstetter, Wayne L
• Format: Journal Article
• Language: English
• Published: United States 10.08.2020
• Subjects: Combined Modality Therapy; Esophageal Neoplasms - pathology; Esophageal Neoplasms - therapy; Humans; Randomized Controlled Trials as Topic
• ISSN: 0732-183X; 1527-7755
• DOI: 10.1200/jco.20.00866

To develop an evidence-based clinical practice guideline to assist in clinical decision making for patients with locally advanced esophageal cancer. ASCO convened an Expert Panel to conduct a systematic review of the more recently published literature (1999-2019) on therapy options for patients with locally advanced esophageal cancer and provide recommended care options for this patient population. Seventeen randomized controlled trials met the inclusion criteria. Where possible, data were extracted separately for squamous cell carcinoma and adenocarcinoma. Multimodality therapy for patients with locally advanced esophageal carcinoma is recommended. For the subgroup of patients with adenocarcinoma, preoperative chemoradiotherapy or perioperative chemotherapy should be offered. For the subgroup of patients with squamous cell carcinoma, preoperative chemoradiotherapy or chemoradiotherapy without surgery should be offered. Additional subgroup considerations are provided to assist with implementation of these recommendations. Additional information is available at www.asco.org/gastrointestinal-cancer-guidelines.